SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:19265e9e-af48-464f-85ac-843b0c09abb7"
 

Search: onr:"swepub:oai:lup.lub.lu.se:19265e9e-af48-464f-85ac-843b0c09abb7" > Use, patient select...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Danchin, NicolasParis Descartes University (author)

Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • 2016-01-27
  • Oxford University Press (OUP),2016
  • 16 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:19265e9e-af48-464f-85ac-843b0c09abb7
  • https://lup.lub.lu.se/record/19265e9e-af48-464f-85ac-843b0c09abb7URI
  • https://doi.org/10.1093/ehjcvp/pvw003DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Aims Among acute coronary syndromes (ACS), ST-segment elevation myocardial infarction (STEMI) has the most severe early clinical course. We aimed to describe the effectiveness and safety of P2Y12 receptor inhibitors in patients with STEMI based on the data from contemporary European ACS registries. Methods and results Twelve registries provided data in a systematic manner on outcomes in STEMI patients overall, and seven of these also provided data for P2Y12 receptor inhibitor-based dual antiplatelet therapy. The registrieswere heterogeneous in terms of site, patient, and treatment selection, as well as in definition of endpoints (e.g. bleeding events). All-cause death rates based on the data from 84 299 patients (9612 patients on prasugrel, 11 492 on ticagrelor, and 27 824 on clopidogrel) ranged between 0.49 and 6.68% in-hospital, between 3.07 and 7.95% at 30 days (reported in 6 registries), between 8.15 and 9.13% at 180 days, and between 2.41 and 9.58% at 1 year (5 registries). Major bleeding rates were 0.09-3.55% inhospital (8 registries), 0.09-1.65% at 30 days, and 1.96% at 1 year (only 1 registry). Fatal/life-Threatening bleeding was rare occurring between 0.08 and 0.13% in-hospital (4 registries) and 1.96% at 1 year (1 registry). Conclusions Real-world evidence from European contemporary registries shows that death, ischaemic events, and bleeding rates are lower than those reported in Phase III studies of P2Y12 inhibitors. Regarding individual P2Y12 inhibitors, patients on prasugrel, and, to a lesser degree, ticagrelor, had fewer ischaemic and bleeding events at all time points than clopidogrel-Treated patients. These findings are partly related to the fact that the newer agents are used in younger and less ill patients.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lettino, MaddalenaHumanitas Research Hospital (author)
  • Zeymer, UweInstitute for Cardiac Arrest Research, Ludwigshafen (author)
  • Widimsky, PetrCharles University in Prague (author)
  • Bardaji, AlfredoHospital Joan XXIII (author)
  • Barrabes, Jose A.Vall d'Hebron University Hospital (author)
  • Cequier, AngelBellvitge University Hospital-IDIBELL (author)
  • Claeys, Marc J.Antwerp University Hospital (author)
  • De Luca, LeonardoEuropean Hospital (author)
  • Dörler, JakobMedical University of Innsbruck (author)
  • Erlinge, DavidLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital(Swepub:lu)kard-der (author)
  • Erne, PaulUniversity of Zurich (author)
  • Goldstein, PatrickLille University Hospital (author)
  • Koul, Sasha M.Skåne University Hospital(Swepub:lu)med-sku (author)
  • Lemesle, GillesLille University Hospital (author)
  • Lüscher, Thomas F.University Hospital of Zurich (author)
  • Matter, Christian M.University Hospital of Zurich (author)
  • Montalescot, GillesPitié-Salpêtrière University Hospital (author)
  • Radovanovic, DraganaUniversity of Zurich (author)
  • Sendón, Jose LopezUniversity Hospital La Paz (author)
  • Tousek, PetrCharles University in Prague (author)
  • Weidinger, FranzHospital Rudolfstiftung (author)
  • Weston, Clive F.M.Swansea University (author)
  • Zaman, AzfarUniversity of Newcastle upon Tyne (author)
  • Andell, PontusSkåne University Hospital(Swepub:lu)med-poa (author)
  • Li, JinUniversity Hospital of Zurich (author)
  • Jukema, J. WouterLeiden University Medical Centre (author)
  • Paris Descartes UniversityHumanitas Research Hospital (creator_code:org_t)
  • the PIRAEUS group

Related titles

  • In:European Heart Journal - Cardiovascular Pharmacotherapy: Oxford University Press (OUP)2:3, s. 152-1672055-68372055-6845

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view